title: Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality.
abstract: The influence of kinetic patterns of Candida albicans germ tube antibodies (CAGTA) on mortality was analyzed in six intensive care units. Statistically significant lower mortality rates were found in patients with patterns of increasing CAGTA titers who had been treated with antifungal agents. Thus, antifungal treatment should be considered when CAGTA titers are increasing in critically ill patients.
authors.affiliation: Intensive Care Unit and Department of Microbiology, Valencia, Spain. zaragozar@ono.com
authors.forename: Rafael
authors.initials: R
authors.lastname: Zaragoza
authors.forename: Javier
authors.initials: J
authors.lastname: Pemán
authors.forename: Guillermo
authors.initials: G
authors.lastname: Quindós
authors.forename: Jose R
authors.initials: JR
authors.lastname: Iruretagoyena
authors.forename: María S
authors.initials: MS
authors.lastname: Cuétara
authors.forename: Paula
authors.initials: P
authors.lastname: Ramírez
authors.forename: Maria D
authors.initials: MD
authors.lastname: Gómez
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Camarena
authors.forename: Angel
authors.initials: A
authors.lastname: Viudes
authors.forename: José
authors.initials: J
authors.lastname: Pontón
mesh_terms: D000908:Antibodies, Fungal / Q000097:blood*; D000935:Antifungal Agents / Q000627:therapeutic use; D002176:Candida albicans / Q000276:immunology*; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality*; D016638:Critical Illness; D006801:Humans; D007700:Kinetics; D012189:Retrospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D000908:Antibodies, Fungal; D000935:Antifungal Agents
references.citation: Clin Microbiol Infect. 2009 Jun;15(6):592-5
references.pmid: 19438621
references.citation: Clin Infect Dis. 2006 Jul 1;43(1):25-31
references.pmid: 16758414
references.citation: Enferm Infecc Microbiol Clin. 2004 Feb;22(2):83-8
references.pmid: 14756989
references.citation: Crit Care. 2005 Oct 5;9(5):485-9
references.pmid: 16277737
references.citation: Rev Iberoam Micol. 2004 Mar;21(1):10-4
references.pmid: 15458356
references.citation: Infect Immun. 1998 May;66(5):2154-62
references.pmid: 9573102
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
references.pmid: 16127033
references.citation: Rev Iberoam Micol. 2001 Mar;18(1):42-4
references.pmid: 15482014
references.citation: Rev Iberoam Micol. 2006 Jun;23(2):59-63
references.pmid: 16854178
references.citation: Med Mycol. 2004 Aug;42(4):319-24
references.pmid: 15473356
references.citation: Rev Iberoam Micol. 2000 Sep;17(3):93-6
references.pmid: 15762800